Type
- ARTG (494)
- Cancellation by sponsor (465)
- Australian Public Assessment Report (AusPAR) (63)
- Prescription medicine registration (41)
- Section 14, TGO91 consent (21)
- Prescription medicine decision summary (19)
- Designation or determination (9)
- Cancellation or suspension (7)
- Prescription medicine evaluation (2)
Date
- 2024 (62)
- 2023 (73)
- 2022 (61)
- 2021 (126)
- 2020 (107)
- 2019 (98)
- 2018 (98)
- 2017 (74)
- 2016 (12)
- 2015 (22)
- 2014 (23)
- 2013 (9)
- 2012 (9)
- 2011 (14)
- 2010 (29)
- 2009 (13)
- 2008 (6)
- 2007 (12)
- 2006 (8)
- 2005 (4)
- 2004 (8)
- 2003 (9)
- 2002 (13)
- 2001 (8)
- 2000 (22)
- 1999 (12)
- 1998 (12)
- 1997 (18)
- 1996 (8)
- 1995 (3)
- 1994 (33)
- 1993 (19)
- 1992 (8)
- 1991 (88)
Results for
"[search-keyword]"
Sponsor content
1121 result(s) found, displaying 21 to 30
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LITFULO ritlecitinib (as tosylate) 50 mg hard capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ELREXFIO elranatamab 76 mg/1.9 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ELREXFIO elranatamab 44 mg/1.1 mL solution for injection vial.
-
Prescription medicine registrationActive ingredients: talazoparib tosilate.
-
Australian Public Assessment Report (AusPAR)Cibinqo (Abrocitinib) is approved for the treatment of moderate-to-severe atopic dermatitis in adults.
-
Australian Public Assessment Report (AusPAR)Tukysa (tucatinib) has been approved to be used in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2 positive unresectable or metastatic colorectal cancer.
-
Prescription medicine decision summaryLitfulo (ritlecitinib) has been approved for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older. Alopecia areata is an autoimmune disease that causes hair loss.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VELSIPITY etrasimod 2 mg tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VELSIPITY etrasimod 2 mg tablet blister pack.
-
Prescription medicine decision summaryElrexfio (elranatamab) has been provisionally approved for the treatment of adult patients with relapsed or refractory multiple myeloma and who have not benefited from 3 prior therapies.